Luciana Marinelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4351648/publications.pdf

Version: 2024-02-01

66343 123424 5,296 137 42 61 citations h-index g-index papers 145 145 145 7629 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5411-5416.	7.1	187
2	The Gâ€Triplex DNA. Angewandte Chemie - International Edition, 2013, 52, 2269-2273.	13.8	133
3	Docking Studies on αvβ3 Integrin Ligands:  Pharmacophore Refinement and Implications for Drug Design. Journal of Medicinal Chemistry, 2003, 46, 4393-4404.	6.4	116
4	Structural and Conformational Requisites in DNA Quadruplex Groove Binding: Another Piece to the Puzzle. Journal of the American Chemical Society, 2010, 132, 6425-6433.	13.7	111
5	Sampling protein motion and solvent effect during ligand binding. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1467-1472.	7.1	100
6	Characterizing the 1,4-Dihydropyridines Binding Interactions in the L-Type Ca2+Channel:Â Model Construction and Docking Calculations. Journal of Medicinal Chemistry, 2007, 50, 1504-1513.	6.4	95
7	Probing Integrin Selectivity: Rational Design of Highly Active and Selective Ligands for the α5β1 and αvβ3 Integrin Receptor. Angewandte Chemie - International Edition, 2007, 46, 3571-3574.	13.8	95
8	Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications. European Journal of Medicinal Chemistry, 2011, 46, 2797-2806.	5 . 5	94
9	Design, Synthesis, and Functionalization of Dimeric Peptides Targeting Chemokine Receptor CXCR4. Journal of Medicinal Chemistry, 2011, 54, 7648-7662.	6.4	93
10	Tandem Application of Virtual Screening and NMR Experiments in the Discovery of Brand New DNA Quadruplex Groove Binders. Journal of the American Chemical Society, 2009, 131, 16336-16337.	13.7	86
11	Novel Bifunctional Quinolonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors:  Design, Synthesis, Biological Activities, and Mechanism of Action. Journal of Medicinal Chemistry, 2006, 49, 1939-1945.	6.4	82
12	Ligand Binding Analysis for Human $\hat{l}\pm5\hat{l}^21$ Integrin: \hat{A} Strategies for Designing New $\hat{l}\pm5\hat{l}^21$ Integrin Antagonists. Journal of Medicinal Chemistry, 2005, 48, 4204-4207.	6.4	77
13	Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Scientific Reports, 2015, 5, 9956.	3.3	77
14	Conformational Control of Integrinâ€Subtype Selectivity in <i>i>iso</i> DGR Peptide Motifs: A Biological Switch. Angewandte Chemie - International Edition, 2010, 49, 9278-9281.	13.8	76
15	Design, Synthesis, and Biological Evaluation of Novel Aminobisphosphonates Possessing an in Vivo Antitumor Activity Through a γÎ-T Lymphocytes-Mediated Activation Mechanism. Journal of Medicinal Chemistry, 2008, 51, 6800-6807.	6.4	70
16	Multiple N-Methylation by a Designed Approach Enhances Receptor Selectivity. Journal of Medicinal Chemistry, 2007, 50, 5878-5881.	6.4	68
17	Rational Improvement of the Affinity and Selectivity of Integrin Binding of Grafted Lasso Peptides. Journal of Medicinal Chemistry, 2014, 57, 5829-5834.	6.4	68
18	Biselectivity of isoDGR Peptides for Fibronectin Binding Integrin Subtypes $\hat{l}\pm5\hat{l}^21$ and $\hat{l}\pm\nu\hat{l}^26$: Conformational Control through Flanking Amino Acids. Journal of Medicinal Chemistry, 2013, 56, 1509-1519.	6.4	67

#	Article	IF	Citations
19	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. Oncotarget, 2016, 7, 20636-20654.	1.8	66
20	Imidazo[2,1- <i>b</i>]thiazole System: A Scaffold Endowing Dihydropyridines with Selective Cardiodepressant Activity. Journal of Medicinal Chemistry, 2008, 51, 1592-1600.	6.4	65
21	Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function. Scientific Reports, 2015, 5, 16478.	3.3	65
22	Regulation of HuR structure and function by dihydrotanshinone-I. Nucleic Acids Research, 2017, 45, 9514-9527.	14.5	64
23	Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma. Scientific Reports, 2014, 4, 4749.	3.3	62
24	<i>N-O-</i> Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis. Journal of Medicinal Chemistry, 2009, 52, 4757-4773.	6.4	60
25	Stable Peptides Instead of Stapled Peptides: Highly Potent αvβ6â€Selective Integrin Ligands. Angewandte Chemie - International Edition, 2016, 55, 1535-1539.	13.8	59
26	Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget, 2017, 8, 77110-77120.	1.8	59
27	Conformational Analysis of Furanoid ε-Sugar Amino Acid Containing Cyclic Peptides by NMR Spectroscopy, Molecular Dynamics Simulation, and X-ray Crystallography:Â Evidence for a Novel Turn Structure. Journal of the American Chemical Society, 2003, 125, 10822-10829.	13.7	56
28	Human Integrin αvβ5: Homology Modeling and Ligand Binding. Journal of Medicinal Chemistry, 2004, 47, 4166-4177.	6.4	55
29	Increasing αvβ3 Selectivity of the Antiâ€Angiogenic Drug Cilengitide by Nâ€Methylation. Angewandte Chemie - International Edition, 2011, 50, 9496-9500.	13.8	54
30	Shooting for Selective Druglike G-Quadruplex Binders: Evidence for Telomeric DNA Damage and Tumor Cell Death. Journal of Medicinal Chemistry, 2012, 55, 9785-9792.	6.4	53
31	Basic Quinolinonyl Diketo Acid Derivatives as Inhibitors of HIV Integrase and their Activity against RNase H Function of Reverse Transcriptase. Journal of Medicinal Chemistry, 2014, 57, 3223-3234.	6.4	51
32	New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer. Journal of Medicinal Chemistry, 2015, 58, 5789-5807.	6.4	51
33	Novel <i>N</i> ² -Substituted Pyrazolo[3,4- <i>d</i>)]pyrimidine Adenosine A ₃ Receptor Antagonists: Inhibition of A ₃ -Mediated Human Glioblastoma Cell Proliferation ^{â€} . Journal of Medicinal Chemistry, 2010, 53, 3954-3963.	6.4	50
34	Exploring the Chemical Space of G-Quadruplex Binders: Discovery of a Novel Chemotype Targeting the Human Telomeric Sequence. Journal of Medicinal Chemistry, 2013, 56, 9646-9654.	6.4	48
35	A Novel Cell-Permeable, Selective, and Noncompetitive Inhibitor of KAT3 Histone Acetyltransferases from a Combined Molecular Pruning/Classical Isosterism Approach. Journal of Medicinal Chemistry, 2015, 58, 2779-2798.	6.4	48
36	Acetic Acid Aldose Reductase Inhibitors Bearing a Five-Membered Heterocyclic Core with Potent Topical Activity in a Visual Impairment Rat Model. Journal of Medicinal Chemistry, 2008, 51, 3182-3193.	6.4	47

#	Article	IF	CITATIONS
37	Protein Flexibility in Virtual Screening: The BACE-1 Case Study. Journal of Chemical Information and Modeling, 2012, 52, 2697-2704.	5.4	47
38	Discovery of Covalent Inhibitors of Glyceraldehyde-3-phosphate Dehydrogenase, A Target for the Treatment of Malaria. Journal of Medicinal Chemistry, 2014, 57, 7465-7471.	6.4	47
39	Probiotic species in the modulation of the anticancer immune response. Seminars in Cancer Biology, 2017, 46, 182-190.	9.6	47
40	Novel Quinolinonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, and Biological Activities. Journal of Medicinal Chemistry, 2008, 51, 4744-4750.	6.4	45
41	New Insight into the Central Benzodiazepine Receptor–Ligand Interactions: Design, Synthesis, Biological Evaluation, and Molecular Modeling of 3-Substituted 6-Phenyl-4 <i>H</i> -imidazo[1,5- <i>a</i>][1,4]benzodiazepines and Related Compounds. Journal of Medicinal Chemistry, 2011, 54, 5694-5711.	6.4	45
42	Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for Glycogen Synthase Kinase-3α. Journal of Medicinal Chemistry, 2012, 55, 4407-4424.	6.4	45
43	A Conformationally Frozen Peptoid Boosts CXCR4 Affinity and Antiâ€HIV Activity. Angewandte Chemie - International Edition, 2012, 51, 8110-8113.	13.8	45
44	Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells. ACS Chemical Neuroscience, 2017, 8, 100-114.	3.5	45
45	Retromer stabilization results in neuroprotection in a model of Amyotrophic Lateral Sclerosis. Nature Communications, 2020, 11, 3848.	12.8	44
46	Ensemble-Docking Approach on BACE-1: Pharmacophore Perception and Guidelines for Drug Design. ChemMedChem, 2007, 2, 667-678.	3.2	43
47	Phenylpyrazolo[1,5- $\langle i \rangle$ a $\langle i \rangle$] quinazolin-5(4 $\langle i \rangle$ H $\langle i \rangle$)-one: A Suitable Scaffold for the Development of Noncamptothecin Topoisomerase I (Top1) Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 7458-7462.	6.4	43
48	Progresses in the pursuit of aldose reductase inhibitors: The structure-based lead optimization step. European Journal of Medicinal Chemistry, 2012, 51, 216-226.	5.5	41
49	Structure–Activity Relationship Refinement and Further Assessment of 4-Phenylquinazoline-2-carboxamide Translocator Protein Ligands as Antiproliferative Agents in Human Glioblastoma Tumors. Journal of Medicinal Chemistry, 2014, 57, 2413-2428.	6.4	41
50	Endogenous vs Exogenous Allosteric Modulators in GPCRs: A dispute for shuttling CB1 among different membrane microenvironments. Scientific Reports, 2015, 5, 15453.	3.3	41
51	Structure-Based Lead Optimization and Biological Evaluation of BAX Direct Activators as Novel Potential Anticancer Agents. Journal of Medicinal Chemistry, 2015, 58, 2135-2148.	6.4	41
52	State-of-the-Art Methodologies for the Discovery and Characterization of DNA G-Quadruplex Binders. Current Pharmaceutical Design, 2012, 18, 1880-1899.	1.9	40
53	Design, Synthesis, and Biological Evaluation of 1-Phenylpyrazolo[3,4- <i>e</i>)pyrrolo[3,4- <i>g</i>)lindolizine-4,6(1 <i>H</i> ,5 <i>H</i>)-diones as New Glycogen Synthase Kinase-31² Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 10066-10078.	6.4	39
54	Interfering with HuR–RNA Interaction: Design, Synthesis and Biological Characterization of Tanshinone Mimics as Novel, Effective HuR Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 1483-1498.	6.4	39

#	Article	IF	Citations
55	Boosting Fmoc Solid-Phase Peptide Synthesis by Ultrasonication. Organic Letters, 2019, 21, 6378-6382.	4.6	39
56	Homology Modeling of NR2B Modulatory Domain of NMDA Receptor and Analysis of Ifenprodil Binding. ChemMedChem, 2007, 2, 1498-1510.	3.2	38
57	Ethyl 8-Fluoro-6-(3-nitrophenyl)-4 <i>H</i> -imidazo[1,5- <i>a</i>][1,4]benzodiazepine-3-carboxylate as Novel, Highly Potent, and Safe Antianxiety Agent. Journal of Medicinal Chemistry, 2008, 51, 4730-4743.	6.4	38
58	Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2013, 62, 379-394.	5.5	38
59	<i>N</i> -Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase. Journal of Medicinal Chemistry, 2015, 58, 4610-4623.	6.4	38
60	Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor-α Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell Models. Journal of Medicinal Chemistry, 2010, 53, 2622-2635.	6.4	37
61	Pursuing Aldose Reductase Inhibitors through in Situ Cross-Docking and Similarity-Based Virtual Screening. Journal of Medicinal Chemistry, 2009, 52, 5578-5581.	6.4	36
62	Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 2617-2629.	5.5	36
63	Breaking the Dogma of the Metalâ€Coordinating Carboxylate Group in Integrin Ligands: Introducing Hydroxamic Acids to the MIDAS To Tune Potency and Selectivity. Angewandte Chemie - International Edition, 2009, 48, 4436-4440.	13.8	35
64	Pharmacophoric Modifications Lead to Superpotent $\hat{l}\pm\hat{v}^2$ 3 Integrin Ligands with Suppressed $\hat{l}\pm5\hat{l}^2$ 1 Activity. Journal of Medicinal Chemistry, 2014, 57, 3410-3417.	6.4	35
65	Pharmacological folding chaperones act as allosteric ligands of Frizzled4. Nature Chemical Biology, 2015, 11, 280-286.	8.0	35
66	The ring residue proline 8 is crucial for the thermal stability of the lasso peptide caulosegnin II. Molecular BioSystems, 2016, 12, 1106-1109.	2.9	35
67	Ligand Based Approach to L-Type Calcium Channel by Imidazo[2,1- <i>b</i>)thiazole-1,4-Dihydropyridines: from Heart Activity to Brain Affinity. Journal of Medicinal Chemistry, 2013, 56, 3866-3877.	6.4	34
68	p53 Functional Inhibitors Behaving Like Pifithrin- \hat{l}^2 Counteract the Alzheimer Peptide Non- \hat{l}^2 -amyloid Component Effects in Human SH-SY5Y Cells. ACS Chemical Neuroscience, 2014, 5, 390-399.	3.5	34
69	Annurca (<i>Malus pumila</i> Miller cv. Annurca) apple as a functional food for the contribution to a healthy balance of plasma cholesterol levels: results of a randomized clinical trial. Journal of the Science of Food and Agriculture, 2017, 97, 2107-2115.	3.5	34
70	Selective Targeting of Integrin $\hat{l}\pm v\hat{l}^28$ by a Highly Active Cyclic Peptide. Journal of Medicinal Chemistry, 2019, 62, 2024-2037.	6.4	33
71	Syntheses, Biological Evaluation, and Molecular Modeling of 18F-Labeled 4-Anilidopiperidines as \hat{l} 4-Opioid Receptor Imaging Agents. Journal of Medicinal Chemistry, 2005, 48, 7720-7732.	6.4	32
72	Deepening the Topology of the Translocator Protein Binding Site by Novel <i>N</i> , <i>N</i> -Dialkyl-2-arylindol-3-ylglyoxylamides. Journal of Medicinal Chemistry, 2015, 58, 6081-6092.	6.4	31

#	Article	IF	Citations
73	Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvl²3. Angewandte Chemie - International Edition, 2017, 56, 16405-16409.	13.8	30
74	Synthesis and Biological Evaluation of CTP Synthetase Inhibitors as Potential Agents for the Treatment of African Trypanosomiasis. ChemMedChem, 2012, 7, 1623-1634.	3.2	29
7 5	3-Aryl-[1,2,4]triazino[4,3- <i>a</i>]benzimidazol-4(10 <i>H</i>)-one: A Novel Template for the Design of Highly Selective A _{2B} Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 1490-1499.	6.4	28
76	Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation. Bioorganic and Medicinal Chemistry, 2015, 23, 7053-7060.	3.0	28
77	Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas. Journal of Medicinal Chemistry, 2016, 59, 4526-4538.	6.4	28
78	Identification of Anxiolytic/Nonsedative Agents among Indol-3-ylglyoxylamides Acting as Functionally Selective Agonists at the \hat{I}^3 -Aminobutyric Acid-A (GABA _A) \hat{I}_{\pm} ₂ Benzodiazepine Receptor. Journal of Medicinal Chemistry, 2009, 52, 3723-3734.	6.4	27
79	Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies. Journal of Medicinal Chemistry, 2011, 54, 1401-1420.	6.4	27
80	Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists. Journal of Medicinal Chemistry, 2016, 59, 8369-8380.	6.4	26
81	From a Helix to a Small Cycle: Metadynamicsâ€Inspired αvβ6 Integrin Selective Ligands. Angewandte Chemie - International Edition, 2018, 57, 14645-14649.	13.8	26
82	A more detailed picture of the interactions between virtual screening-derived hits and the DNA G-quadruplex: NMR, molecular modelling and ITC studies. Biochimie, 2011, 93, 1280-1287.	2.6	25
83	Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: A first round of lead optimization. European Journal of Medicinal Chemistry, 2012, 47, 143-152.	5 . 5	25
84	Urotensin-II Receptor Ligands. From Agonist to Antagonist Activity. Journal of Medicinal Chemistry, 2005, 48, 7290-7297.	6.4	24
85	Benzofuroxane Derivatives as Multi-Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2012, 55, 10523-10531.	6.4	24
86	Shading the TRF2 Recruiting Function: A New Horizon in Drug Development. Journal of the American Chemical Society, 2014, 136, 16708-16711.	13.7	23
87	Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)–Ligand Interactions on Living Cancer Cells. Journal of Medicinal Chemistry, 2018, 61, 2910-2923.	6.4	22
88	Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells. ACS Chemical Neuroscience, 2018, 9, 85-99.	3.5	22
89	Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme. Journal of Medicinal Chemistry, 2018, 61, 4791-4809.	6.4	22
90	Structureâ^'Activity Relationship Studies Optimizing the Antiproliferative Activity of Novel Cyclic Somatostatin Analogues Containing a Restrained Cyclic β-Amino Acidâ€. Journal of Medicinal Chemistry, 2005, 48, 2916-2926.	6.4	21

#	Article	IF	CITATIONS
91	Beyond radio-displacement techniques for Identification of CB1 Ligands: The First Application of a Fluorescence-quenching Assay. Scientific Reports, 2014, 4, 3757.	3.3	21
92	A Healthy Balance of Plasma Cholesterol by a Novel Annurca Apple-Based Nutraceutical Formulation: Results of a Randomized Trial. Journal of Medicinal Food, 2017, 20, 288-300.	1.5	21
93	Structure–Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist. Journal of Medicinal Chemistry, 2017, 60, 9641-9652.	6.4	21
94	Receptorâ∈Bound Conformation of Cilengitide Better Represented by Its Solutionâ∈State Structure than the Solidâ∈State Structure. Chemistry - A European Journal, 2014, 20, 14201-14206.	3.3	20
95	Clickâ€Chemistry (CuAAC) Trimerization of an α _v β ₆ Integrin Targeting Gaâ€68â€Peptide: Enhanced Contrast for inâ€Vivo PET Imaging of Human Lung Adenocarcinoma Xenografts. ChemBioChem, 2020, 21, 2836-2843.	2.6	20
96	Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell Models. Journal of Medicinal Chemistry, 2013, 56, 8089-8103.	6.4	19
97	Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma. European Journal of Medicinal Chemistry, 2016, 118, 47-63.	5.5	19
98	Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure–Activity Relationship Studies and Pharmacological Activity. Journal of Medicinal Chemistry, 2017, 60, 8115-8130.	6.4	19
99	Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3 . Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies Journal of Medicinal Chemistry, 2014, 57, 1225-1235.	6.4	18
100	Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands. European Journal of Medicinal Chemistry, 2015, 90, 526-536.	5.5	18
101	Screening Platform toward New Anti-HIV Aptamers Set on Molecular Docking and Fluorescence Quenching Techniques. Analytical Chemistry, 2016, 88, 2327-2334.	6.5	18
102	<i>N</i> -Methylation of <i>iso</i> DGR Peptides: Discovery of a Selective α5β1-Integrin Ligand as a Potent Tumor Imaging Agent. Journal of Medicinal Chemistry, 2018, 61, 2490-2499.	6.4	18
103	Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides. Journal of Medicinal Chemistry, 2019, 62, 1455-1467.	6.4	18
104	A stereoselective approach to peptidomimetic BACE1 inhibitors. European Journal of Medicinal Chemistry, 2013, 70, 233-247.	5.5	17
105	Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells. Oncotarget, 2016, 7, 7866-7884.	1.8	17
106	Design, synthesis and biological evaluation of novel $TR\hat{l}^2$ selective agonists sustained by ADME-toxicity analysis. European Journal of Medicinal Chemistry, 2020, 188, 112006.	5.5	16
107	Interfering with the Tumor–Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 16020-16045.	6.4	16
108	Synthesis, Molecular Modeling, and Opioid Receptor Affinity of 9,10-Diazatricyclo[4.2.1.12,5]decanes and 2,7-Diazatricyclo[4.4.0.03,8]decanes Structurally Related to 3,8-Diazabicyclo[3.2.1]octanes. Journal of Medicinal Chemistry, 2000, 43, 2115-2123.	6.4	15

#	Article	IF	Citations
109	Designed Beta-Turn Mimic Based on the Allylic-Strain Concept: Evaluation of Structural and Biological Features by Incorporation into a Cyclic RGD Peptide (Cyclo(-L-arginylglycyl-Laspartyl-)). Helvetica Chimica Acta, 2002, 85, 4442-4452.	1.6	15
110	Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations. Journal of Medicinal Chemistry, 2009, 52, 1224-1228.	6.4	15
111	Novel peptidomimetics as BACE-1 inhibitors: Synthesis, molecular modeling, and biological studies. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 85-89.	2.2	15
112	Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. European Journal of Pharmaceutical Sciences, 2020, 149, 105337.	4.0	15
113	New 2-Heterocyclyl-imidazo[2,1- <i>i</i>) purin-5-one Derivatives as Potent and Selective Human A ₃ Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2011, 54, 5205-5220.	6.4	14
114	Human recombinant beta-secretase immobilized enzyme reactor for fast hits' selection and characterization from a virtual screening library. Journal of Pharmaceutical and Biomedical Analysis, 2013, 73, 131-134.	2.8	14
115	The organometallic ferrocene exhibits amplified anti-tumor activity by targeted delivery via highly selective ligands to $\hat{l}\pm v\hat{l}^2$ 3, $\hat{l}\pm v\hat{l}^2$ 6, or $\hat{l}\pm 5\hat{l}^2$ 1 integrins. Biomaterials, 2021, 271, 120754.	11.4	14
116	N-O-Isopropyl sulfonamido-based hydroxamates: Kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors. Biochemical Pharmacology, 2012, 84, 813-820.	4.4	13
117	Chemical modifications in the seed region of miRNAs 221/222 increase the silencing performances in gastrointestinal stromal tumor cells. European Journal of Medicinal Chemistry, 2016, 111, 15-25.	5.5	13
118	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors. European Journal of Medicinal Chemistry, 2018, 150, 491-505.	5.5	13
119	Tailoring of Integrin Ligands: Probing the Charge Capability of the Metal Ion-Dependent Adhesion Site. Journal of Medicinal Chemistry, 2012, 55, 871-882.	6.4	12
120	Water-Soluble Pyrazolo[4,3- <i>e</i>][1,2,4]triazolo[1,5- <i>c</i>]pyrimidines as Human A ₃ Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 5380-5390.	6.4	11
121	Stabile Peptide statt "gestapelte Peptide― hochaffine αvβ6â€selektive Integrinliganden. Angewandte Chemi 2016, 128, 1559-1563.	e 2.0	11
122	CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme. European Journal of Pharmacology, 2021, 897, 173936.	3.5	11
123	HuR-targeted agents: An insight into medicinal chemistry, biophysical, computational studies and pharmacological effects on cancer models. Advanced Drug Delivery Reviews, 2022, 181, 114088.	13.7	11
124	Cationic nucleopeptides as novel non-covalent carriers for the delivery of peptide nucleic acid (PNA) and RNA oligomers. Bioorganic and Medicinal Chemistry, 2018, 26, 2539-2550.	3.0	10
125	Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 737-749.	4.1	10
126	Disulfide Bond Replacement with 1,4―and 1,5â€Disubstituted [1,2,3]â€Triazole on Câ€X Chemokine Recept Type 4 (CXCR4) Peptide Ligands: Small Changes that Make Big Differences. Chemistry - A European Journal, 2020, 26, 10113-10125.	or 3.3	10

#	Article	IF	CITATIONS
127	Halting the Spread of Herpes Simplex Virus-1: The Discovery of an Effective Dual αvβ6/αvβ8 Integrin Ligand. Journal of Medicinal Chemistry, 2021, 64, 6972-6984.	6.4	9
128	Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. Journal of Medicinal Chemistry, 2021, 64, 3449-3461.	6.4	8
129	Siteâ€directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Nonâ€Nucleoside Inhibitors. Chemical Biology and Drug Design, 2016, 87, 112-120.	3.2	6
130	From the Pharmacophore to the Homology Model of the Benzodiazepine Receptor: The Indolyglyoxylamides Affair. Current Topics in Medicinal Chemistry, 2012, 12, 321-332.	2.1	5
131	Lösung des Problems mangelnder oraler Verfügbarkeit cyclischer Hexapeptide: Entwicklung eines selektiven, oral verfügbaren Liganden für das Integrin αvβ3. Angewandte Chemie, 2017, 129, 16624-16	629 ⁰	5
132	Benzothiopyranoindole- and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases. European Journal of Medicinal Chemistry, 2019, 165, 46-58.	5.5	5
133	Von einer Helix zu einem kleinen Ring: Metadynamikâ€inspirierte, selektive Liganden für αvβ6â€Integrin. Angewandte Chemie, 2018, 130, 14856-14860.	2.0	3
134	Highly Selective Cyclic Hexapeptides Antagonist of GPIIb-IIIa by Multiple N-Methylation. Advances in Experimental Medicine and Biology, 2009, 611, 209-210.	1.6	3
135	Synthesis and NMR Structure of Peptidomimetic α4β7-Integrin Antagonists. ChemBioChem, 2002, 3, 575.	2.6	2
136	Ensemble-Docking Approach on BACE-1: Pharmacophore Perception and Guidelines for Drug Design. ChemMedChem, 2007, 2, 740-740.	3.2	2
137	Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of $\hat{I}\pm5\hat{I}^21$ Integrin. Cancers, 2022, 14, 369.	3.7	2